Clinical trials: Older Adults With Cancer
Osteosarcoma, Neoplasms, Connective Tissue
Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
Two cycles of neoadjuvant three-component chemotherapy according to the MAP prototoc: Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration.
- Conditions
- Osteosarcoma, Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Sarcoma
- Trial name
- NCT05057130
- Testing
- Doxorubicin, Cisplatin, Methotrexate, Doxorubicin, Cisplatin
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Lymphoma, Large-Cell, Diffuse
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
The primary objective of this study is to evaluate the efficacy of doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) plus rituximab in comparison to cyclophosphamide, doxorubicin, vincristine, prednisone…
- Trial name
- NCT00135499
- Testing
- Rituximab, Doxorubicin, Cyclophosphamide
- Where
- 8 sites in Belgium, France and 1 more
- Volunteers
- 138 people
- Sponsor
- Lymphoma Study Association
Colorectal Cancer, Sarcopenia
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
- Trial name
- M&M (NCT03998202)
- Where
- 147 sites in United States
- Volunteers
- 300 people
- Sponsor
- Wake Forest University Health Sciences
Acute Myeloid Leukemia
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
The purpose of this study is to determine the side effects of the study drug, clofarabine, when given by mouth to patients with acute myeloid leukemia (AML), in remission.
- Trial name
- NCT01065545
- Testing
- Clofarabine
- Sponsor
- Northwestern University
Acute Myelogenous Leukemia
Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)
This Phase 1b study will determine the maximum tolerated dose of KX2-391 given as a once-daily dose, in elderly patients with acute myelogenous leukemia.
- Trial name
- NCT01397799
- Testing
- KX2-391
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Kinex Pharmaceuticals Inc.
Lymphoma, Large B-Cell, Diffuse
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and…
- Trial name
- ROBUST (NCT02285062)
- Testing
- lenalidomide, Rituximab, Cyclophosphamide
- Where
- 158 sites in United States, Australia and 19 more
- Volunteers
- 570 people
- Sponsor
- Celgene
Diffuse Large B Cell Lymphoma
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
This prospective, single-arm, multicenter clinical study aims to enroll 30 frail elderly patients with Non-GCB DLBCL. This study is to evaluate the preliminary efficacy and safety of the combination of Polatuzumab, Rituximab, and…
- Trial name
- NCT06530511
- Testing
- Polatuzumab vedotin, Rituximab, Orelabrutinib
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Geriatric Assessment, Geriatric Patients
Development and Verification of a Screening Tool for Comprehensive Geriatric Assessment of Elderly Tumor Patients
This study is an observational research. 1. The study first conducted an electronic questionnaire survey among clinicians working in general and specialized hospitals at various levels nationwide to understand the implementation…
- Conditions
- Geriatric Assessment, Geriatric Patients, Patients With Cancer, Assessment Tool
- Trial name
- NCT06761534
- Testing
- Screening of comprehensive geriatic assessment., the G8 assessment, Comprehensive Geriatric Assessment (CGA)
- Where
- China
- Volunteers
- 678 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Esophageal Cancer, Oesophageal Cancer
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
Cancer - including esophageal squamous cell cancer (ESCC) - is a disease of the elderly but little is known about the biology and progression of cancers in these patients.
- Conditions
- Esophageal Cancer, Oesophageal Cancer, Oesophageal Cancer Metastatic, Esophageal Cancer Metastatic
- Trial name
- RAMONA (NCT03416244)
- Testing
- Nivolumab, Ipilimumab
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- AIO-Studien-gGmbH
Non-small Cell Lung Cancer Stage IV
Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC
Explore the efficacy and safety of Envafolimab in first line treatment of elderly patients with locally advanced or metastatic non-small cell lung cancer with high PD-L1 expression, view to providing better treatment options for…
- Trial name
- NCT05055167
- Testing
- Envafolimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Esophageal Cancer, Chemoradiation
S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer
This was a randomised, multicenter, phase 3 trial. Patients who were age of 70 years or older with histologically confirmed esophageal cancer were randomly assigned to S-1 concurrent with radiotherapy or radiotherapy alone.The…
- Trial name
- NCT02813967
- Testing
- Radiotherapy 54 Gy, Radiotherapy 60 Gy, S-1
- Where
- China
- Volunteers
- 298 people
- Sponsor
- Zhejiang Cancer Hospital
Non-Small Cell Lung Cancer, Carcinoma
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC
- Conditions
- Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma
- Trial name
- ABOUND 70+ (NCT02151149)
- Testing
- nab-paclitaxel, Carboplatin
- Where
- 55 sites in United States
- Volunteers
- 143 people
- Sponsor
- Celgene
AML (Acute Myelogenous Leukemia
Fitness in Elderly AML Patients
The study aims to evaluate the outcome of patients (overall survival) who received treatments commensurate with the proposed "Fitness" parameters compared to that of patients whose treatment differed either in the direction of…
- Trial name
- AML-FITNESS (NCT07598838)
- Testing
- Fitness Categories: FIT, UNFIT and FRAIL
- Where
- Italy
- Volunteers
- 725 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Leukemia
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to…
- Trial name
- AML-17 (NCT00052299)
- Testing
- cytarabine, etoposide, gemtuzumab ozogamicin
- Where
- 55 sites in Austria, Belgium and 5 more
- Volunteers
- 472 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Diffuse Large B Cell Lymphoma
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
This is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of the Zanubrutinib, Lenalidomide and Rituximab (ZR2) regimen in elderly treatment-naive patient with…
- Trial name
- NCT04460248
- Testing
- Zanubrutinib, Lenalidomide and Rituximab (ZR2)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Breast Cancer, Elderly
Gene Polymorphisms and Gene Products as Biological Markers of Aging and Correlation With Clinical Geriatric Assessment, Tolerance of Chemotherapy and Outcome in Elderly Breast Cancer Patients
The goal is to study the biology of aging in breast cancer patients, and to study the impact of chemotherapy on aging related blood biomarkers.
- Trial name
- EBS (NCT00849758)
- Where
- 2 sites in Belgium
- Volunteers
- 110 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
CCND1 Positive, CD20-Positive Neoplastic Cells Present
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
This phase II trial studies how well ibrutinib plus rituximab and lenalidomide work in treating elderly participants with newly diagnosed mantle cell lymphoma.
- Conditions
- CCND1 Positive, CD20-Positive Neoplastic Cells Present, Mantle Cell Lymphoma
- Trial name
- NCT03232307
- Testing
- Dexamethasone, Ibrutinib, Lenalidomide
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma (GBM)
Hypofractionated Radiotherapy Plus Temozolamide in Patients Younger Than 70 Years With Glioblastoma
The goal of this clinical trial is to evaluate the feasibility, safety and effectiveness of radiotherapy with fewer days of treatment and a higher dose of radiation each day in patients under 70 years of age diagnosed with a…
- Trial name
- HipoGBM (NCT07492836)
- Testing
- Hypofractionated Radiation Therapy
- Volunteers
- 10 people
- Sponsor
- Hospital do Coracao
Multiple Myeloma
Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma
IFM 2012-03 protocol is a Phase 2 multicenter nonrandomized open in elderly patients with multiple myeloma at diagnosis. Study primary objectives are in the first step to determine Maximum tolerated dose (MTD) of Carfilzomib…
- Trial name
- IFM2012-03 (NCT02302495)
- Testing
- Carfilzomib
- Where
- 33 sites in France
- Volunteers
- 32 people
- Sponsor
- University Hospital, Lille
Papillomavirus Infections
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
This study will evaluate the efficacy, immunogenicity and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese women 20 to 45 years of age.
- Trial name
- NCT03998254
- Testing
- V503, Gardasil
- Where
- 6 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.